文献速递临床试验与 GCP

儿童孤独症沟通治疗(PACT)对比常规管理治疗孤独症儿童:丹麦全国实用性随机临床试验DAN-PACT方案

Paediatric Autism Communication Therapy (PACT) versus management as usual in autistic children: a protocol for a Danish pragmatic, national, randomised clinical trial: DAN-PACT.
PubMed 文献 · Trials · 2025-08-29

DAN-PACT是一项研究者发起的多中心、平行组、优效性随机临床试验,计划纳入280名2.0-6.9岁新诊断孤独症儿童,比较PACT联合常规管理与单纯常规管理。主要结局为ADOS-2 CSS测量的孤独症特征程度,样本量基于最小重要差异0.66分计算。

要点

  • DAN-PACT为多中心、平行组、优效性随机临床试验,计划纳入280名2.0-6.9岁新诊断孤独症儿童。
  • 主要结局为ADOS-2 CSS测量的孤独症特征程度,样本量基于最小重要差异0.66分。
  • 次要结局包括BOSCC测量的社交沟通技能、VABS-3测量的适应技能及亲子生活质量。

核心结论

  • DAN-PACT旨在最小化偏倚风险、将试验锚定于自然临床环境,并扩展既往PACT研究的结局测量范围。
  • 试验局限性包括数据缺失风险、无法对家长参与者及其对部分次要和探索性结局的评分设盲,以及ADOS-2 CSS和BOSCC的最小重要差异幅度尚无共识而采用务实估计。

研究设计与样本

  • DAN-PACT为研究者发起、独立资助、多中心、平行组、优效性随机临床试验。
  • 计划纳入来自丹麦各地区的280名2.0-6.9岁新诊断孤独症儿童。
  • 比较PACT联合常规管理与单纯常规管理。
  • 主要结局评估者、数据管理员、统计师和结论绘制者设盲。
  • 试验人员将接受PACT和增强常规管理的培训,评估PACT的手工保真度,并通过重复测量评估广泛获益与危害。

主要发现

  • 主要结局为ADOS-2 CSS测量的孤独症特征程度。
  • 样本量计算基于最小重要差异0.66分,对应ADOS原始分2-3分差异。
  • 次要结局包括BOSCC测量的儿童社交沟通技能变化、VABS-3测量的儿童适应技能变化,以及家长对自身和儿童生活质量的评估。
  • 探索性结局包括试验期间的不良事件。

关键数值与推荐

  • 主要结局为ADOS-2 CSS测量的孤独症特征程度。
  • 样本量计算基于最小重要差异0.66分,对应ADOS原始分2-3分差异。
  • 次要结局为BOSCC测量的儿童社交沟通技能变化、VABS-3测量的儿童适应技能变化,以及家长对自身和儿童生活质量的评估。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 数据缺失风险。
  • 无法对家长参与者及其对部分次要和探索性结局的评分设盲。
  • ADOS-2 CSS和BOSCC的最小重要差异幅度尚无共识,因此采用务实估计。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Despite autism being a lifelong developmental condition affecting approximately 2% of children and young people worldwide, interventions aimed at improving core autism features are sparse. Paediatric Autism Communication Therapy (PACT) is among the first parent-mediated developmental interventions, provided in naturalistic settings, to show promising results in core feature improvement. METHODS: DAN-PACT is an investigator-initiated, independently funded, multicentre, parallel group superiority, randomised clinical trial, which aims to assess benefits and harms of PACT in 2.0-6.9-year-old children with a recent autism diagnosis, comparing PACT combined with management as usual to management as usual alone. Two hundred eighty autistic children from all regions of Denmark will be included. Primary outcome assessors, data managers, statisticians, and conclusion drawers will be blinded. The primary outcome is magnitude of autism features as measured by the ADOS-2 CSS. The sample size calculation is based on a minimal important difference of 0.66 points, corresponding to a 2-3-point difference in ADOS raw scores. Secondary outcomes are changes in child social communication skills measured with the BOSCC, child adaptive skills measured with the VABS-3, and parents' assessment of their own and their child's quality of life. Several exploratory outcomes will be assessed, including adverse events during the trial period. Trial staff will be trained to perform both PACT and enhanced management as usual, assessing manual fidelity of PACT and measuring a broad range of benefits and harms with repeated measures. DISCUSSION: DAN-PACT aims to minimise risks of bias, anchor the trial in a naturalistic clinical setting, and extend the scope of outcome measures used in previous PACT studies, achieved by blinding raters to all observational outcomes, including a large sample of young autistic children, and using an enhanced management as usual control sample. Trial limitations are the risk of missing data and the inability to blind parent participants to their group allocation and their rating of several secondary and exploratory outcomes. In addition, there is no consensus on the magnitude of the minimal important difference on ADOS-2 CSS or BOSCC, which are therefore estimated pragmatically. TRIAL REGISTRATION: ClinicalTrials.gov NCT05673096. Registered on December 22, 2022.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Ziegler SMT, Jeppesen P, Christiansen J, et al. Paediatric Autism Communication Therapy (PACT) versus management as usual in autistic children: a protocol for a Danish pragmatic, national, randomised clinical trial: DAN-PACT. Trials. 2025. PMID: 40883837. doi:10.1186/s13063-025-09017-z

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。